bluuebunny/crossref_metadata_2025_split huggingface dataset:
Parent-of-origin effectrough endospermmutants in maize
Authors: Bai Fang , Daliberti Mary , Bagadion Alyssa , Xu Miaoyun , Li Yubing , Baier John , Tseung Chi Wah , Evans Matthew M. S. , Settles A. Mark 
Published: May 2016

ABSTRACTParent-of-origin effect loci have non-Mendelian inheritance in which phenotypes are determined by either the maternal or paternal allele alone. In angiosperms, parent-of-origin effects can be caused by loci required for gametophyte development or by imprinted genes needed for seed development. Few parent-of-origin effect loci have been identified in maize (Zea mays) even though there are a large number of imprinted genes known from transcriptomics. We screenedrough endosperm(rgh) mutants for parent-of-origin effects using reciprocal crosses with inbred parents. Sixmaternal rough endosperm(mre) and threepaternal rough endosperm(pre) mutants were identified with threemreloci mapped. When inherited from the female parent,mre/+ seeds reduce grain-fill with a rough, etched, or pitted endosperm surface. Pollen transmission ofpremutants results inrghendosperm as well as embryo lethality. Eight of the loci had significant distortion from the expected one-to-one ratio for parent-of-origin effects. Linked markers formre1,mre2, andmre3indicated that the mutant alleles have no bias in transmission. Histological analysis ofmre1,mre2,mre3, andpre*-949showed altered timing of starch grain accumulation and basal endosperm transfer cell layer (BETL) development. Themre1locus delays BETL and starchy endosperm development, whilemre2andpre*-949cause ectopic starchy endosperm differentiation. We conclude that many parent-of-origin effects in maize have incomplete penetrance of kernel phenotypes and that there is a large diversity of endosperm developmental roles for parent-of-origin effect loci.
Clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction
Authors: Deveau Paul , Colmet Daage Leo , Oldridge Derek , Bernard Virginie , Bellini Angela , Chicard Mathieu , Clement Nathalie , Lapouble Eve , Combaret Valérie , Boland Anne , Meyer Vincent , Deleuze Jean-François , Janoueix-Lerosey Isabelle , Barillot Emmanuel , Delattre Olivier , Maris John , Schleiermacher Gudrun , Boeva Valentina 
Published: May 2016

AbstractIn cancer, clonal evolution is characterized based on single nucleotide variants and copy number alterations. Nonetheless, previous methods failed to combine information from both sources to accurately reconstruct clonal populations in a given tumor sample or in a set of tumor samples coming from the same patient. Moreover, previous methods accepted as input all variants predicted by variant-callers, regardless of differences in dispersion of variant allele frequencies (VAFs) due to uneven depth of coverage and possible presence of strand bias, prohibiting accurate inference of clonal architecture. We present a general framework for assignment of functional mutations to specific cancer clones, which is based on distinction between passenger variants with expected low dispersion of VAF versus putative functional variants, which may not be used for the reconstruction of cancer clonal architecture but can be assigned to inferred clones at the final stage. The key element of our framework is QuantumClone, a method to cluster variants into clones, which we have thoroughly tested on simulated data. QuantumClone takes into account VAFs and genotypes of corresponding regions together with information about normal cell contamination. We applied our framework to whole genome sequencing data for 19 neuroblastoma trios each including constitutional, diagnosis and relapse samples. We discovered specific pathways recurrently altered by deleterious mutations in different clonal populations. Some such pathways were previously reported (e.g., MAPK and neuritogenesis) while some were novel (e.g., epithelial-mesenchymal transition, cell survival and DNA repair). Most pathways and their modules had more mutations at relapse compared to diagnosis.
The Open Innovation – Strategy nexus: findings from the Mobile Telecommunications Industry
Authors: Ghezzi Antonio , Balocco Raffaello , Rangone Andrea 
Published: May 2016

Purpose
This study aims to recognize the growing importance of Open Innovation (OI) theory and practice in the broader fields of Management and Information Systems, and focuse on the relationship existing between OI and a firm’s Business Strategy. Hence, the study aims at investigating the multifaceted OI – Strategy nexus at a business level, assessing how OI initiatives influence Strategy within the Mobile Telecommunications Industry and thus contributing to framing and classifying such inherent relationship.

Design/methodology/approach
A data-driven research approach is used, based on 45 qualitative interviews on firms operating in the Mobile Industry and involved in OI initiatives.

Findings
Six cross-themes the OI–Strategy relationship in the Mobile Industry revolves around are identified, i.e. OI and Competitive Advantage; OI and Strategic Positioning; OI and Business Models; OI in Networks; OI and Co-opetition; and OI and Resilient Business Advantages. For each theme, examples from the sample of interviewed Mobile firms are organized and reported. The key managerial issues emerging in the attempt to relate OI initiatives and the firm’s overarching Strategy are also underscored and organized in three streams, namely, designing an open business model; achieving competitive advantage through value capture; and nurturing OI as a dynamic capability.

Originality/value
The proposed reorganization of real-world OI and strategic initiatives in the Mobile Industry, together with the underscoring of key managerial issues, constitutes a comprehensive research agenda or roadmap, with value for both academics and practitioners.
Characteristics Associated with Home Health Care Referrals at Hospital Discharge: Results from the 2012 National Inpatient Sample
Authors: Jones Christine D. , Wald Heidi L. , Boxer Rebecca S. , Masoudi Frederick A. , Burke Robert E. , Capp Roberta , Coleman Eric A. , Ginde Adit A. 
Published: May 2016

ObjectiveTo assess patient‐ and hospital‐level factors associated with home health care (HHC) referrals following nonelective U.S. patient hospitalizations in 2012.Data SourceThe 2012 National Inpatient Sample (NIS).Study DesignRetrospective, cross‐sectional multivariable logistic regression modeling to assess patient‐ and hospital‐level variables in patient discharges with versus without HHC referrals.Data CollectionAnalysis included 1,109,905 discharges in patients ≥65 years with Medicare.Principal FindingsAbout 29.2 percent of discharges were referred to HHC, which were more likely with older age, female sex, urban location, low income, longer length of stay, higher severity of illness scores, diagnoses of heart failure or sepsis, and hospital location in New England (referent: Pacific).ConclusionsAs health policy changes influence postacute HHC, defining specific diagnoses and regional patterns associated with HHC is a first step to optimize postacute HHC services.
The Effect of Physician and Hospital Market Structure on Medical Technology Diffusion
Authors: Karaca‐Mandic Pinar , Town Robert J. , Wilcock Andrew 
Published: May 2016

ObjectiveTo examine the influence of physician and hospital market structures on medical technology diffusion, studying the diffusion of drug‐eluting stents (DESs), which became available in April 2003.Data Sources/Study SettingMedicare claims linked to physician demographic data from the American Medical Association and to hospital characteristics from the American Hospital Association Survey.Study DesignRetrospective claims data analyses.Data Collection/Extraction MethodsAll fee‐for‐service Medicare beneficiaries who received a percutaneous coronary intervention (PCI) with a cardiac stent in 2003 or 2004. Each PCI record was joined to characteristics on the patient, the procedure, the cardiologist, and the hospital where the PCI was delivered. We accounted for the endogeneity of physician and hospital market structure using exogenous variation in the distances between patient, physician, and hospital locations. We estimated multivariate linear probability models that related the use of a DES in the PCI on market structure while controlling for patient, physician, and hospital characteristics.Principal FindingsDESs diffused faster in markets where cardiology practices faced more competition. Conversely, we found no evidence that the structure of the hospital market mattered.ConclusionsCompetitive pressure to maintain or expand PCI volume shares compelled cardiologists to adopt DESs more quickly.
Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity
Authors: Aminkeng Folefac , Ross Colin J. D. , Rassekh Shahrad R. , Hwang Soomi , Rieder Michael J. , Bhavsar Amit P. , Smith Anne , Sanatani Shubhayan , Gelmon Karen A. , Bernstein Daniel , Hayden Michael R. , Amstutz Ursula , Carleton Bruce C. ,   CPNDS Clinical Practice Recommendations Group
Published: May 2016

AimsAnthracycline‐induced cardiotoxicity (ACT) occurs in 57% of treated patients and remains an important limitation of anthracycline‐based chemotherapy. In various genetic association studies, potential genetic risk markers for ACT have been identified. Therefore, we developed evidence‐based clinical practice recommendations for pharmacogenomic testing to further individualize therapy based on ACT risk.MethodsWe followed a standard guideline development process, including a systematic literature search, evidence synthesis and critical appraisal, and the development of clinical practice recommendations with an international expert group.ResultsRARG rs2229774, SLC28A3 rs7853758 and UGT1A6 rs17863783 variants currently have the strongest and the most consistent evidence for association with ACT. Genetic variants in ABCC1, ABCC2, ABCC5, ABCB1, ABCB4, CBR3, RAC2, NCF4, CYBA, GSTP1, CAT, SULT2B1, POR, HAS3, SLC22A7, SCL22A17, HFE and NOS3 have also been associated with ACT, but require additional validation. We recommend pharmacogenomic testing for the RARG rs2229774 (S427L), SLC28A3 rs7853758 (L461L) and UGT1A6*4 rs17863783 (V209V) variants in childhood cancer patients with an indication for doxorubicin or daunorubicin therapy (Level B – moderate). Based on an overall risk stratification, taking into account genetic and clinical risk factors, we recommend a number of management options including increased frequency of echocardiogram monitoring, follow‐up, as well as therapeutic options within the current standard of clinical practice.ConclusionsExisting evidence demonstrates that genetic factors have the potential to improve the discrimination between individuals at higher and lower risk of ACT. Genetic testing may therefore support both patient care decisions and evidence development for an improved prevention of ACT.
Population pharmacokinetics and prophylactic anti‐emetic efficacy of ramosetron in surgical patients
Authors: Lee Yong‐Hun , Seo Jae‐Hyeon , Min Kyung‐Tae , Lim Young‐Jin , Jeong Seong‐Wook , Lee Eun‐Kyung , Choi Byung‐Moon , Noh Gyu‐Jeong 
Published: May 2016

AimsThis study characterized the pharmacokinetics of ramosetron and compared prophylactic anti‐emetic efficacy with that of ondansetron in a large population.MethodsFifty‐eight patients consented to the pharmacokinetic analysis and were assigned randomly to receive 0.3, 0.45 or 0.6 mg ramosetron after induction of anaesthesia. Blood samples were acquired at preset intervals. Non‐compartmental and population pharmacokinetic analyses were performed. In total, 1102 patients consented to the evaluation of prophylactic anti‐emetic efficacy and were allocated randomly to receive 0.3 mg ramosetron or 4 mg ondansetron at the end of surgery. An additional 16 mg ondansetron were mixed in the intravenous patient‐controlled analgesia pump of the ondansetron group. Post‐operative nausea and vomiting (PONV) were evaluated 6, 24 and 48 h post‐operatively using the Rhodes index of nausea, vomiting and retching (RINVR). Administration of rescue anti‐emetics and adverse events were evaluated.ResultsThe pharmacokinetic parameter estimates were V1 (l) = 5.12, V2 (l) = 108, CL (l⋅min−1) = 0.08 + (59⋅age−1) × 0.09, Q (l⋅min−1) = 1.42. The incidences of PONV in the ramosetron and ondansetron groups were 77 (13.9%) and 113 (20.6%) and 44 (7.9%) and 66 (12.0%) at 24 and 48 h post‐operatively, respectively (P = 0.004, 0.030). RINVR was significantly lower in the ramosetron than the ondansetron group 24 and 48 h post‐operatively (P = 0.003, 0.025). Use of rescue anti‐emetics and incidence of adverse events were comparable.ConclusionsA two compartment mammillary model was used to describe ramosetron pharmacokinetics. Prophylactic anti‐emetic efficacy of ramosetron was significantly better 24 and 48 h post‐operatively than that of ondansetron, particularly when the Apfel score was ≥ 3.
The impact of a medication review with follow‐up service on hospital admissions in aged polypharmacy patients
Authors: Malet‐Larrea Amaia , Goyenechea Estíbaliz , García‐Cárdenas Victoria , Calvo Begoña , Arteche Jose M. , Aranegui Pedro , Zubeldia Jose J. , Gastelurrutia Miguel A. , Martínez‐Martínez Fernando , Benrimoj Shalom I. 
Published: May 2016

AbstractAimsThe aims were to assess the impact of a medication review with follow‐up (MRF) service provided in community pharmacy to aged polypharmacy patients on the number of medication‐related hospital admissions and to estimate the effect on hospital costs.MethodsThis was a sub‐analysis of a cluster randomized controlled trials carried out in 178 community pharmacies in Spain. Pharmacies in the intervention group (IG) provided a comprehensive medication review during 6 months. Pharmacists in the comparison group (CG) delivered usual care. For the purposes of this sub‐analysis, an expert panel of three internal medicine specialists screened the hospitalizations occurring during the main study, in order to identify medication‐related hospitalizations. Inter‐rater reliability was measured using Fleiss's kappa. Hospital costs were calculated using diagnosis related groups.ResultsOne thousand four hundred and three patients were included in the main study and they had 83 hospitalizations. Forty‐two hospitalizations (50.6%) were medicine‐related, with a substantial level of agreement among the experts (kappa = 0.65, 95% CI 0.52, 0.78, P < 0.01). The number of medication‐related hospitalizations was significantly lower in patients receiving MRF (IG 11, GC 31, P = 0.042). The probability of being hospitalized was 3.7 times higher in the CG (odds ratio 3.7, 95% CI 1.2, 11.3, P = 0.021). Costs for a medicine‐related hospitalization were €6672. Medication‐related hospitalization costs were lower for patients receiving MRF [IG: €94 (SD 917); CG: €301 (SD 2102); 95% CI 35.9, 378.0, P = 0.018].ConclusionMRF provided by community pharmacists might be an effective strategy to balance the assurance of the benefit from medications and the avoidance of medication‐related hospitalizations in aged patients using polypharmacy.
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis
Authors: Gupta Neeraj , Hanley Michael J. , Harvey R. Donald , Badros Ashraf , Lipe Brea , Kukreti Vishal , Berdeja Jesus , Yang Huyuan , Hui Ai‐Min , Qian Mark , Zhang Xiaoquan , Venkatakrishnan Karthik , Chari Ajai 
Published: May 2016

SummaryRenal impairment (RI) is a major complication of multiple myeloma (MM). This study aimed to characterize the single‐dose pharmacokinetics (PK) of the oral proteasome inhibitor, ixazomib, in cancer patients with normal renal function [creatinine clearance (CrCl) ≥90 ml/min; n = 20), severe RI (CrCl <30 ml/min; n = 14), or end‐stage renal disease requiring haemodialysis (ESRD; n = 7). PK and adverse events (AEs) were assessed after a single 3 mg dose of ixazomib. Ixazomib was highly bound to plasma proteins (~99%) in all renal function groups. Unbound and total systemic exposures of ixazomib were 38% and 39% higher, respectively, in severe RI/ESRD patients versus patients with normal renal function. Total ixazomib concentrations were similar in pre‐ and post‐dialyser samples collected from ESRD patients; therefore, ixazomib can be administered without regard to haemodialysis timing. Except for anaemia, the incidence of the most common AEs was generally similar across groups, but grade 3 and 4 AEs were more frequent in the severe RI/ESRD groups versus the normal group (79%/57% vs. 45%), as were serious AEs (43%/43% vs. 15%). The PK and safety results support a reduced ixazomib dose of 3 mg in patients with severe RI/ESRD.
Movement Assessment of Children (MAC): validity, reliability, stability and sensitivity to change in typically developing children
Authors: Chandler L. S. , Terhorst L. , Rogers J. C. , Holm M. B. 
Published: May 2016

AbstractAimThe purpose of this study was to establish the validity, reliability, stability and sensitivity to change of the family‐centred Movement Assessment of Children (MAC) in typically developing infants/toddlers from 2 months (1 month 16 days) to 2 years (24 months 15 days) of age.BackgroundAssessment of infant/toddler motor development is critical so that infants and toddlers who are at‐risk for developmental delay or whose functional motor development is delayed can be monitored and receive therapy to improve their developmental outcomes. Infants/toddlers are thought to be more responsive during the MAC assessment because parents and siblings participate and elicit responses.MethodsTwo hundred seventy six children and 405 assessments contributed to the establishment of age‐related parameters for typically developing infants and toddlers on the MAC. The MAC assesses three core domains of functional movement (head control, upper extremities and hands, pelvis and lower extremities), and generates a core total score. Four explanatory domains serve to alert examiners to factors that may impact atypical development (general observations, special senses, primitive reflexes/reactions, muscle tone). Construct validity of functional motor development was examined using the relationship between incremental increases in scores and increases in participants' ages. Subsamples were used to establish inter‐rater reliability, test–retest reliability, stability and sensitivity to change.ResultsConstruct validity was established and inter‐rater reliability ICCs for the core items and core total ranged from 0.83 to 0.99. Percent agreement for the explanatory items ranged from 0.72 to 0.96. Stability within age grouping was consistent from baseline to 6 months post‐baseline, and sensitivity to change from baseline to 6 months was significant for all core items and the total score.ConclusionThe MAC has proven to be a well‐constructed assessment of infant and toddler functional motor development. It is a family‐centred and efficient tool that can be used to assess and follow‐up of infants and toddlers from 2 months to 2 years.
Immediate‐type hypersensitivity to polyethylene glycols: a review
Authors: Wenande E. , Garvey L. H. 
Published: May 2016

SummaryPolyethylene glycols (PEGs) or macrogols are polyether compounds widely used in medical and household products. Although generally considered biologically inert, cases of mild to life‐threatening immediate‐type PEG hypersensitivity are reported with increasing frequency. Nevertheless, awareness of PEG's allergenic potential remains low, due to a general lack of suspicion towards excipients and insufficient product labelling. Information on immediate‐type reactions to PEG is limited to anecdotal reports, and the potential for PEG sensitization and cross‐sensitization to PEGylated drugs and structurally related derivatives is likely underestimated. Most healthcare professionals have no knowledge of PEG and thus do not suspect PEG's as culprit agents in hypersensitivity reactions. In consequence, patients are at risk of misdiagnosis and commonly present with a history of repeated, severe reactions to a range of unrelated products in hospital and at home. Increased awareness of PEG prevalence, PEG hypersensitivity, and improved access to PEG allergy testing, should facilitate earlier diagnosis and reduce the risk of inadvertent re‐exposure. This first comprehensive review provides practical information for allergists and other healthcare professionals by describing the clinical picture of 37 reported cases of PEG hypersensitivity since 1977, summarizing instances where PEG hypersensitivity should be considered and proposing an algorithm for diagnostic management.
Implant‐Supported Immediately Loaded Fixed Full‐Arch Dentures: Evaluation of Implant Survival Rates in a Case Cohort of up to 7 Years
Authors: Niedermaier Robert , Stelzle Florian , Riemann Max , Bolz Wolfgang , Schuh Paul , Wachtel Hannes 
Published: May 2016

ABSTRACTBackgroundThe treatment of severely atrophied and edentulous jaws by means of fixed implant supported solutions is a challenging procedure.PurposeThe immediate loading of four to six axial and tilted implants offers the possibility to overcome elaborate hard tissue augmentation procedures but lacks implant and patient related data on implant survival rates.Materials and MethodsThis retrospective 7‐years clinical trial investigated the implant survival rates of 2,081 implants (380 patients, 482 jaws) using an immediate loading protocol with either 4, 5, or 6 implants per restoration. Survival rates were calculated concerning implantation related factors (jaws/number of supporting implants/angulations/diameters/lengths) and patient related factors (medical status/smoking).ResultsOverall survival of 2,081 implants was 97.0% on implant level. Survival rates of implantation related factors did not yield significant differences. Significant differences were yield between healthy patients and patients with osteoporosis (p = .002) and the medical status group “other” (p = .032), respectively. Smokers yielded a significantly higher survival than nonsmokers (p = .002).ConclusionsIt is assumed that four implants per jaw serve as a sufficient implant number for full arch restorations in both, the mandible and the maxilla. Osteoporosis under the medication with bisphosphonates seems to be a risk factor for implant survival. The authors suggest that the effect of smoking on ISRs remains controversial within this treatment concept.